Clinical trial

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

NCT01526057

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-03-20

PhasePHASE2

Study timeline

Study start (actual)2012-03-20Date precision: day

Registry last updated2019-11-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Rheumatoid Arthritisunresolved

Interventions

PF-05280586BIOLOGICAL

MabTheraBIOLOGICAL

RituxanBIOLOGICAL

Sponsors & collaborators

Pfizerlead sponsor

Mapped research locations

WorcesterMassachusetts, United States3 LeedsUnited Kingdom3 Los AngelesCalifornia, United States2 BirminghamAlabama, United States2 Saint PetersburgRussia2 QuébecQuebec, Canada2 MaywoodIllinois, United States2 HoustonTexas, United States1 PhiladelphiaPennsylvania, United States1 DallasTexas, United States1 LondonUnited Kingdom1 CincinnatiOhio, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01526057 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.